Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Aug 22, 2024

BUY
$0.79 - $2.83 $35,222 - $126,178
44,586 New
44,586 $38,000
Q2 2021

Aug 11, 2021

SELL
$18.57 - $35.68 $11.5 Million - $22.2 Million
-621,097 Reduced 93.3%
44,586 $1.81 Million
Q1 2021

May 11, 2021

SELL
$31.0 - $55.72 $217,403 - $390,764
-7,013 Reduced 1.04%
665,683 $23.1 Million
Q4 2020

Feb 09, 2021

SELL
$37.09 - $48.97 $13 Million - $17.1 Million
-349,157 Reduced 34.17%
672,696 $25 Million
Q3 2020

Nov 12, 2020

BUY
$40.47 - $45.5 $13.4 Million - $15.1 Million
331,351 Added 47.99%
1,021,853 $42 Million
Q2 2020

Aug 07, 2020

SELL
$32.57 - $42.83 $537,437 - $706,737
-16,501 Reduced 2.33%
690,502 $28 Million
Q1 2020

May 08, 2020

SELL
$23.3 - $45.96 $274,940 - $542,328
-11,800 Reduced 1.64%
707,003 $24.6 Million
Q4 2019

Feb 06, 2020

SELL
$34.58 - $48.06 $1.01 Million - $1.41 Million
-29,324 Reduced 3.92%
718,803 $30.8 Million
Q3 2019

Nov 12, 2019

SELL
$36.98 - $48.45 $627,180 - $821,712
-16,960 Reduced 2.22%
748,127 $27.7 Million
Q2 2019

Aug 12, 2019

BUY
$35.13 - $55.53 $4.8 Million - $7.58 Million
136,567 Added 21.73%
765,087 $34.6 Million
Q1 2019

May 10, 2019

BUY
$42.83 - $59.91 $26.9 Million - $37.7 Million
628,520 New
628,520 $34.2 Million
Q4 2018

Feb 12, 2019

SELL
$37.97 - $60.16 $1.12 Million - $1.77 Million
-29,415 Closed
0 $0
Q3 2018

Nov 13, 2018

SELL
$56.3 - $67.25 $1.49 Million - $1.78 Million
-26,524 Reduced 47.42%
29,415 $1.79 Million
Q2 2018

Aug 02, 2018

SELL
$44.9 - $64.95 $114,090 - $165,037
-2,541 Reduced 4.35%
55,939 $3.5 Million
Q1 2018

May 11, 2018

SELL
$45.35 - $61.65 $220,627 - $299,927
-4,865 Reduced 7.68%
58,480 $2.7 Million
Q4 2017

Feb 09, 2018

SELL
$41.95 - $60.1 $545,224 - $781,119
-12,997 Reduced 17.02%
63,345 $3 Million
Q3 2017

Nov 13, 2017

BUY
$33.4 - $53.9 $2.55 Million - $4.11 Million
76,342
76,342 $4.11 Million

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $32.8M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Fiera Capital Corp Portfolio

Follow Fiera Capital Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fiera Capital Corp, based on Form 13F filings with the SEC.

News

Stay updated on Fiera Capital Corp with notifications on news.